Adaptin Bio (APTN) Change in Accured Expenses (2023 - 2026)

Adaptin Bio's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $256901.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 1256.68% year-over-year to $256901.0; the TTM figure through Mar 2026 stood at $252155.0 (down 73.12% YoY), while the FY2025 annual figure was $14190.0, down 98.33% from the prior year.
• Change in Accured Expenses came in at $256901.0 for Q1 2026 at Adaptin Bio, down from $541624.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $636596.0 in Q2 2024 to a low of -$547190.0 in Q2 2025.
• A 4-year average of $109396.0 and a median of $49612.0 in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses slumped 185.96% in 2025 and surged 1256.68% in 2026, its largest moves.
• Adaptin Bio's Change in Accured Expenses stood at -$28442.0 in 2023, then surged by 811.22% to $202286.0 in 2024, then surged by 167.75% to $541624.0 in 2025, then sank by 52.57% to $256901.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $256901.0, $541624.0, and $820.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison